- 1
- 2
- 3
- 4
Novo Nordisk Returns To Growth, With Growing Pains
ALSO IN THIS MONTH'S ISSUE
-
![Feature 2_Jeff Cleland_Ashvattha_450x300]( "Biotech Veteran Pushes New Science And Regulatory Change")
Biotech Veteran Pushes New Science And Regulatory ChangeAshvattha Therapeutics CEO Jeff Cleland hopes to bring hydroxyl dendrimer therapeutics to market for the first time, while also pushing for policy and regulatory change as an advocate for BIO.
-
![CtW - Nido Bio_450x300]( "Companies To Watch: Nido Biosciences")
Companies To Watch: Nido BiosciencesSee why Nido Biosciences is developing small molecule drugs for rare neurodegenerative diseases.
-
![Leadership Article - Natasha Howard_450x300]( "Leadership Pressures: Causing An Imbalanced Organization")
Leadership Pressures: Causing An Imbalanced OrganizationWe all must do what’s best for our business, our teams (people), and ultimately the patient in a compliant manner. So, what happens if you prioritize one over the other?
-
![IRA Uncertainty_Dan Chancellor_450x300]( "Addressing The Uncertainties Of The IRA In Biopharma")
Addressing The Uncertainties Of The IRA In BiopharmaIn recent years, the biopharma industry has been anything but predictable. But the creation of the Inflation Reduction Act (IRA) of 2022 has added a new layer of uncertainty that reaches most corners of the industry.
WEB-EXCLUSIVE EDITORIAL
NEWSLETTER ARCHIVE
- 09.29.23 -- 3 Traits For Compliance Execs To Become Business Leaders
- 09.28.23 -- Securing Your Consumables Supply Chain
- 09.28.23 -- Innovative Solutions To Ensure CGT Commercial Success
- 09.27.23 -- Launching Drugs In Europe On Time And On Budget
- 09.27.23 -- Enabling Faster Development Timelines With Novel Characterization Approaches
SEPTEMBER 2023 DIGITAL EDITION
LIFE SCIENCE LEADER CONTENT COLLECTIONS
2023 CMO & CRO AWARDS EDITION
ASK THE BOARD
- What Impact Is The Inflation Reduction Act Already Having On Biopharma Companies, And What More Can The Industry Do Going Forward?
- How Can Executives Work Through Tightened Budgets And Manage Tradeoffs While Keeping The Workforce Happy And Motivated?
- How Can Drug Developers Work Together With The FDA To Maximize The Value Of A Clinical Trial Protocol?
- In These Times Of Increasingly Unpredictable And Lurching Change, What Skills Will Separate Out Next-Gen CEOs?
- In Partnering With Academic Institutions To Advance Drug Discovery, What Are The Key Benefits And Challenges?
- In Discussing A Strategic Initiative Presented To The Board By Management, Such As A Bolt-On Acquisition, What Are The Three Core Questions That Boards Should Always Ask?
This website uses cookies to ensure you get the best experience on our website. Learn more